Condition: Clear Cell Renal Cell Carcinoma · Sponsor: Xencor, Inc.
The purpose of this study is to assess the safety and tolerability of XmAb®819 administered intravenous (IV) or subcutaneous (SC) in subjects with relapsed or refractory clear cell renal cell carcinoma and to identify the minimum safe and biologically active dose and the recommended dose (RD).
This description comes directly from the study's public registry record.
Chet Bohac, MD · 819-01info@xencor.com
Lisa Finnigan · 819-01info@xencor.com
Always discuss trial participation with your own doctor first.
| Xencor Investigative Site | Phoenix, Arizona, United States | Recruiting |
| Xencor Investigative Site | Duarte, California, United States | Recruiting |
| Xencor Investigative Site | Sacramento, California, United States | Recruiting |
| Xencor Investigative Site | New Haven, Connecticut, United States | Recruiting |
| Xencor Investigative Site | Jacksonville, Florida, United States | Recruiting |
| Xencor Investigative Site | Atlanta, Georgia, United States | Recruiting |
| Xencor Investigative Site | Chicago, Illinois, United States | Recruiting |
| Xencor Investigative Site | Chicago, Illinois, United States | Recruiting |
| Xencor Investigative Site | Louisville, Kentucky, United States | Recruiting |
| Xencor Investigative Site | Rochester, Minnesota, United States | Recruiting |
| Xencor Investigative Site | New Brunswick, New Jersey, United States | Recruiting |
| Xencor Investigative Site | New York, New York, United States | Recruiting |
+ 14 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05433142